Halozyme Therapeutics competitorsClear all

Blueprint Medicines's top competitors include Karyopharm Therapeutics.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Blueprint Medicines
Blueprint Medicines
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Karyopharm Therapeutics
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
Founding Date
Founding Date
2011
Founding Date
2008
Type
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Cambridge, US HQ
Amsterdam, NL
Lugano, CH
Zug, CH
Cambridge, US
Locations
Newton, US HQ
München, DE
Giv'atayim, IL
Providence, US
Employees
Employees
38376% increase
Employees
481
Alexa Website Rank
Alexa Website Rank
365252
Alexa Website Rank
230559
Employee Rating
Employee Rating
4.2
Employee Rating
3.6

Financial

Revenue (est.)
Revenue (est.)
$793.7m (FY, 2020)
Revenue (est.)
$108.1m (FY, 2020)
Net income
Net income
$313.9m (FY, 2020)
Net income
($196.3m) (FY, 2020)

Funding

Total funding raised
Total funding raised
$ 115m
Total funding raised
$ 248.7m
For sources of this data, please see the company profile

View company profiles

Karyopharm Therapeutics
HQ
Newton, US

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.

View company